TRIAVIL 4-10
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIAVIL 4-10 (TRIAVIL 4-10).
TRIAVIL 4-10 contains perphenazine, a typical antipsychotic that blocks postsynaptic dopamine D1 and D2 receptors in the limbic system, basal ganglia, and hypothalamus, and amitriptyline, a tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake.
| Metabolism | Perphenazine: extensively metabolized by CYP2D6, CYP3A4, and CYP1A2. Amitriptyline: metabolized by CYP2C19 and CYP2D6 to nortriptyline (active). |
| Excretion | Primarily renal (about 50-70% as metabolites, <5% unchanged) and fecal (30-50% via biliary elimination). |
| Half-life | Amitriptyline: 10-28 hours (mean 21 hours); perphenazine: 8-12 hours (mean 10 hours). Clinically, steady-state achieved in 3-5 days for amitriptyline, 2-3 days for perphenazine. |
| Protein binding | Amitriptyline: 96% bound to albumin and alpha-1-acid glycoprotein; perphenazine: 90-95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Amitriptyline: 10-20 L/kg, indicating extensive tissue distribution; perphenazine: 10-25 L/kg, reflecting high lipophilicity and tissue uptake. |
| Bioavailability | Amitriptyline: 45-60% due to first-pass metabolism; perphenazine: 40-60% due to first-pass metabolism; both extensively metabolized by CYP2D6 and CYP3A4. |
| Onset of Action | Oral: antidepressant effect 2-4 weeks; antipsychotic effect 2-7 days; sedative effect 30-60 minutes. |
| Duration of Action | Amitriptyline: 4-8 hours for sedative effects; antidepressant effect persists for days after discontinuation due to active metabolite nortriptyline (half-life 18-44 hours). Perphenazine: 6-12 hours for antipsychotic effect. |
| Molecular Weight | Amitriptyline: 277.4 Da; Perphenazine: 403.9 Da. Combination: Note as individual weights. |
1 tablet (perphenazine 4 mg / amitriptyline 10 mg) orally 3 times daily, maximum 8 tablets daily.
| Dosage form | TABLET |
| Renal impairment | GFR 10-50 mL/min: reduce dose by 50%. GFR <10 mL/min: avoid use. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated. |
| Pediatric use | Not recommended for children <12 years; for adolescents 12-18 years: perphenazine 0.1-0.5 mg/kg/day divided q6-8h, amitriptyline 1-3 mg/kg/day divided q6-8h, maximum perphenazine 16 mg/day, amitriptyline 150 mg/day. |
| Geriatric use | Initial dose: one-half tablet (2 mg/5 mg) orally 2-3 times daily; titrate slowly, maximum perphenazine 24 mg/day, amitriptyline 100 mg/day. |
| 1st trimester | Amitriptyline and perphenazine are both pregnancy category C (FDA). Teratogenic risk: amitriptyline is considered low risk; perphenazine has been associated with congenital malformations in animal studies. Use only if potential benefit outweighs risk. |
| 2nd trimester | Second trimester exposure may be associated with fetal growth restriction. Monitor fetal growth. Both drugs cross the placenta. Risk of extrapyramidal side effects in fetus/newborn if used near term. |
| 3rd trimester | Third trimester use, especially perphenazine, can lead to neonatal extrapyramidal symptoms, withdrawal, or respiratory depression. Avoid in late pregnancy if possible. |
Clinical note
Comprehensive clinical and safety monograph for TRIAVIL 4-10 (TRIAVIL 4-10).
| Placental transfer | Both amitriptyline and perphenazine cross the placenta. Amitriptyline exhibits moderate transfer; perphenazine has limited data but is expected to cross due to lipophilicity. |
| Breastfeeding |
■ FDA Black Box Warning
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders (per amitriptyline). Not approved for pediatric use. Increased mortality in elderly patients with dementia-related psychosis (per perphenazine).
| Serious Effects |
Hypersensitivity to amitriptyline, perphenazine, or any componentConcurrent use with MAOIs (risk of hypertensive crisis)Recent myocardial infarctionUncontrolled narrow-angle glaucomaSevere CNS depression or comaBlood dyscrasiasKnown QT prolongation or concurrent use of QT-prolonging drugs
| Precautions | Suicidality, neuroleptic malignant syndrome, tardive dyskinesia, seizures, anticholinergic effects, cardiotoxicity (QT prolongation), mania/hypomania, sedation, orthostatic hypotension, agranulocytosis, hyperprolactinemia, withdrawal symptoms. |
| Food/Dietary | Avoid alcohol and grapefruit juice. Grapefruit may increase amitriptyline levels. High-tyramine foods (aged cheeses, cured meats, fermented products) can cause hypertensive crisis if taken with MAOIs, but perphenazine and amitriptyline are not MAOIs; however, caution is advised. Maintain adequate fluid intake to counteract anticholinergic effects. |
Loading safety data…
| Both drugs are excreted into breast milk. Amitriptyline levels are low (<1% maternal weight-adjusted dose) and are considered compatible with breastfeeding by the AAP. Perphenazine has limited data; may cause drowsiness or decreased milk supply. Monitor infant for sedation, poor feeding, or extrapyramidal effects. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Increased risk of congenital malformations (cardiovascular, neural tube defects) associated with amitriptyline (FDA category D). Perphenazine (FDA category C) may cause extrapyramidal effects. Second and third trimesters: Risk of neonatal withdrawal (tachycardia, irritability, respiratory distress) and anticholinergic effects. Avoid use, especially after 36 weeks, due to risk of neonatal sedation and withdrawal. |
| Fetal Monitoring | Monitor fetal growth and development with serial ultrasound. Assess for neonatal withdrawal symptoms (e.g., irritability, feeding difficulties, respiratory distress) after delivery. Monitor maternal blood pressure, heart rate, and ECG. Assess for extrapyramidal symptoms and anticholinergic effects. |
| Fertility Effects | Amitriptyline may cause menstrual irregularities and decreased libido; perphenazine may cause galactorrhea, amenorrhea, and reduced fertility due to prolactin elevation. Both may impair fertility. Effects are reversible upon discontinuation. |
| Clinical Pearls | TRIAVIL 4-10 contains perphenazine 4 mg and amitriptyline 10 mg. Monitor for extrapyramidal symptoms (EPS) and tardive dyskinesia with perphenazine; use lowest effective dose. Amitriptyline has anticholinergic effects (dry mouth, constipation, urinary retention) and can cause orthostatic hypotension; caution in elderly and cardiac patients. Avoid abrupt discontinuation; taper to prevent withdrawal. Obtain baseline ECG due to QTc prolongation risk. Avoid coadministration with MAOIs; allow 14-day washout. Use in pregnancy only if benefit outweighs risk (NSH category D). |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without consulting your doctor. · Avoid alcohol; may worsen side effects like drowsiness and dizziness. · Rise slowly from sitting or lying to prevent falls from low blood pressure. · Report any muscle stiffness, tremors, or uncontrolled movements immediately. · Notify doctor if you experience rapid heartbeat, fainting, or suicidal thoughts. · Use caution when driving or operating machinery until you know how this medication affects you. · Inform all healthcare providers you are taking this medication. |